August 1, 2009Pharmacogenomics
Pharmacogenetics of Antihypertensive Treatment: Detailing Disciplinary Dissonance
Key result
A review of 18 studies on hypertension pharmacogenetics found emerging consistent gene-treatment combinations, though limited by heterogeneous designs, phenotypes, and small sample sizes.
Why the study?
Do genetic polymorphisms predict response to antihypertensive drugs in patients with hypertension?
Population
Patients with hypertension
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Emerging consistent signals support targeted validation trials in hypertension; insufficient for clinical adoption.
Structured PICO
Do genetic polymorphisms predict response to antihypertensive drugs in patients with hypertension?
P
Population
Patients with hypertension (review of 18 studies published since 2005 investigating associations between genetic polymorphisms and response to antihypertensive drugs)
E
Exposure
Antihypertensive drugs evaluated for pharmacogenetic associations
O
Outcome
Response to antihypertensive drugs (ranging from blood pressure changes to clinical outcomes)
Pharmacogenetic predictors of antihypertensive response show some consistent gene-treatment combinations, but clinical translation is currently limited by heterogeneous study designs and small sample sizes.
Limitations
- Differences in study designs
- Variable methods for assessing pharmacologic exposures
- Heterogeneous phenotypes
- Small sample sizes
- Short duration of follow-up
- differences in study designs
- variable methods for assessing pharmacologic exposures
- heterogeneous phenotypes
- small sample sizes
- short duration of follow-up
Cite This Study
Arnett et al. (2009) conducted a review in Hypertension. Genetic predictors of response to antihypertensive drugs was evaluated. A review of 18 studies on hypertension pharmacogenetics found emerging consistent gene-treatment combinations, though limited by heterogeneous designs, phenotypes, and small sample sizes.